Back to results
US 2016/0106832 A1Published application
Treatment of cancer with naltrexone
AssigneeCancer Vaccine Institute
InventorsAngus Dalgleish, Rachel Allen
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeCancer Vaccine Institute
InventorsAngus Dalgleish, Rachel Allen
Estimating the term…
The present invention provides novel therapeutic applications of low dose naltrexone (LDN). Said applications have been determined in light of the discovery by the present inventors that naltrexone acts as an antagonist of Toll-like receptor 9 (TLR9), an innate immune receptor which elicits the production of inflammatory cytokines when agonized. Chronic inflammation and TLR9 overexpression are characteristics of a number of disorders, including certain cancers. Accordingly, the present invention provides novel uses of naltrexone in the treatment of a subject having a disorder characterised by TLR9 overexpression and/or overactivity of TLR9-mediated signalling. The present invention also provides novel uses of naltrexone in the supportive care of subject having a tumour/cancer, and methods of treating and providing supportive care to a subject, comprising the administration of naltrexone.
A pharmaceutical composition comprising naltrexone or an analogue thereof, for use in the treatment of a subject having a disorder which is characterised by TLR9 overexpression and/or overactivity of TLR9-mediated signalling.
A pharmaceutical composition according to any preceding claim, wherein the subject is or has been administered at least one chemotherapeutic agent selected from the group consisting of Revlimid, cyclophosphamide, Gemcitabine and carboplatin.
A pharmaceutical composition comprising naltrexone or an analogue thereof, for use in the supportive care of a subject having a tumour/cancer.
A pharmaceutical composition according to any preceding claim, wherein naltrexone, as part of said composition, is to be administered to the subject at a dose between 0.01 mg/kg and 0.08 mg/kg, preferably between 0.03 mg/kg and 0.06 mg/kg, more preferably between 0.04 mg/kg and 0.05 mg/kg.
A method of treating a subject having a disorder which is characterised by TLR9 overexpression and/or overactivity of TLR9-mediated signalling;
A method of providing supportive care to a subject having a tumour/cancer, comprising administering to the subject, a pharmaceutical composition comprising naltrexone or an analogue thereof.
Naltrexone or an analogue thereof, for use as a vaccine adjuvant.
A vaccine composition, comprising naltrexone, or an analogue thereof, and an immunogen.
Naltrexone, or an analogue thereof, for use in the treatment of metastatic melanoma, preferably in combination with Vitamin D3.
Dependencies are inferred from the claim text.